Literature DB >> 7692943

Clonal chromosome abnormalities in human breast carcinomas. I. Twenty-eight cases with primary disease.

F Thompson1, J Emerson, W Dalton, J M Yang, D McGee, H Villar, S Knox, K Massey, R Weinstein, A Bhattacharyya.   

Abstract

Cytogenetic analysis was performed on a selected series of short-term cultures of primary breast carcinomas from 28 patients. All patients had histopathologically confirmed malignancies, with the majority (25/28 cases) demonstrating infiltrating ductal carcinoma. All 28 cases evidenced clonal chromosome abnormalities, with 10/28 displaying only numeric aberrations, whereas 18/28 displayed clonal structural alterations. In near-diploid tumors the most common numeric changes were -17 and -19. However, trisomy 7 was the only numeric change in two near-diploid tumors. Structural chromosome alterations were primarily isochromosomes, apparent terminal deletions, and unbalanced non-reciprocal translocations. Chromosomes I (10/18-56%) and 6 (8/18-44%) were most frequently altered in this series. Breakpoints of clonal structural abnormalities were shown to cluster to several chromosome segments, including 1p22-q11, 3p11, 6p11-13, 7p11-q11, 8p11-q11, and 19q13. Analysis of the gain or loss of specific chromosome segments revealed that the most consistent tendency was over-representation of 1q, 3q, and 6p.

Entities:  

Mesh:

Year:  1993        PMID: 7692943     DOI: 10.1002/gcc.2870070402

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  15 in total

Review 1.  Structural cues from the tissue microenvironment are essential determinants of the human mammary epithelial cell phenotype.

Authors:  K L Schmeichel; V M Weaver; M J Bissell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

Review 2.  Advances in cytogenetic analysis of solid tumours.

Authors:  L James; J Varley
Journal:  Chromosome Res       Date:  1996-11       Impact factor: 5.239

3.  The long and short of chromosome 11 in breast cancer.

Authors:  I F Newsham
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

4.  Genetic heterogeneity of primary and metastatic breast carcinoma defined by fluorescence in situ hybridization.

Authors:  J F Simpson; D E Quan; J P Ho; M L Slovak
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

5.  Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter.

Authors:  J C Rice; B W Futscher
Journal:  Nucleic Acids Res       Date:  2000-09-01       Impact factor: 16.971

6.  Relation between deletion of chromosome 1p36 and DNA ploidy in breast carcinoma: an interphase cytogenetic study.

Authors:  F Farabegoli; N Baldini; D Santini; C Ceccarelli; M Taffurelli; D Treré; M Derenzini
Journal:  Clin Mol Pathol       Date:  1996-04

Review 7.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

8.  The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.

Authors:  George S Watts; Marc M Oshiro; Damian J Junk; Ryan J Wozniak; Summer Watterson; Frederick E Domann; Bernard W Futscher
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

Review 9.  Microdissection and microcloning of chromosomal alterations in human breast cancer.

Authors:  J M Trent; B Weber; X Y Guan; J Zhang; F Collins; K Abel; A Diamond; P Meltzer
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Authors:  George Fountzilas; Urania Dafni; Mattheos Bobos; Vassiliki Kotoula; Anna Batistatou; Ioannis Xanthakis; Christos Papadimitriou; Ioannis Kostopoulos; Triantafillia Koletsa; Eleftheria Tsolaki; Despina Televantou; Eleni Timotheadou; Angelos Koutras; George Klouvas; Epaminontas Samantas; Nikolaos Pisanidis; Charisios Karanikiotis; Ioanna Sfakianaki; Nicholas Pavlidis; Helen Gogas; Helena Linardou; Konstantine T Kalogeras; Dimitrios Pectasides; Meletios A Dimopoulos
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.